Brief: Tarsus Completes Enrollment For Phase 3 Saturn-2 Trial Of TP-03

Tarsus Pharmaceuticals

02/02/2022 12:23

Feb 2 (Reuters) - Tarsus Pharmaceuticals Inc  TARS.O :
    * TARSUS COMPLETES ENROLLMENT FOR THE PIVOTAL PHASE 3
SATURN-2
TRIAL OF TP-03 TO TREAT DEMODEX BLEPHARITIS AND SECURES $175
MILLION CREDIT FACILITY
    * TARSUS PHARMACEUTICALS- ON TRACK TO ADVANCE AND EXPAND OUR
PIPELINE, INCLUDING DELIVERING PIVOTAL PHASE 3 DATA FROM
SATURN-2 , SUBMITTING TP-03 NDA
    * TARSUS PHARMACEUTICALS INC - IF TP-03 NDA APPROVED, 
WELL-POSITIONED FOR OUR EXPECTED COMMERCIAL LAUNCH OF TP-03 NEXT
YEAR
    * TARSUS PHARMACEUTICALS INC - CREDIT FACILITY WITH HERCULES
CAPITAL AND SILICON VALLEY BANK PROVIDES AVAILABILITY OF
NON-DILUTIVE CAPITAL
    * TARSUS PHARMACEUTICALS INC - EXECUTED A $175 MILLION
CREDIT
FACILITY WITH HERCULES CAPITAL, INC AND SILICON VALLEY BANK

Source text for Eikon:  ID:nGNX3GD23z 
Further company coverage:  TARS.O 

 ((Reuters.Briefs@thomsonreuters.com;))